Glitazones clinical data: An update;Données cliniques nouvelles sur les glitazones

Annales d'Endocrinologie

Volumn 66, Issue 2 II, 2005, Pages

  Guerci, B ^a  

^a Ctr Hospitalier Univ de Nancy   (France)

Author keywords

Pioglitazone; Rosiglitazone; Therapeutic; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLIBENCLAMIDE; GLICLAZIDE; GLITAZONE DERIVATIVE; GLUCOSE; INSULIN ASPART; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG MECHANISM; EDEMA; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEMODILUTION; HIGH RISK POPULATION; HUMAN; HYPOGLYCEMIA; INSULIN SENSITIVITY; LIVER TOXICITY; METABOLISM; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; REVIEW; SIDE EFFECT;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; THIAZOLIDINEDIONES;

EID: 17744396734     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Ferré P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 2004; 53: S43-S50.
2. Ferré P. Adiponectine: de l'adipocyte au muscle. Ann Endocrinol 2004; 65: 1S36-1S43.
3. Pégorier JP, Girard J. Thiazolidinediones et insulinosensibilité: rôle du récepteur nucléaire PPARγ. Ann Endocrinol 2004; 65: 65-72.
4. Pégorier JP. Récepteurs PPAR et insulinosensibilité: nouveaux agonistes en développement. Ann Endocrinol 2005; 66: 1S10-1S17.
5. Rask E, Olsson T, Soderberg S, et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001; 86: 1418-21.
6. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC, Grino M. Expression of the mRNA coding for 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 2002; 87: 2701-5.
7. Whorwood CB, Donovan SJ, Flanagan D, Phillips DIW, Byrne CD. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes 2002; 51: 1066-75.
8. Stulnig TM, Waldhäusl W. 11β-hydroxysteroid dehydrogenase type 1 in obesity and type 2 diabetes. Diabetologia 2004; 47: 1-11.
9. Reynolds RM, Walker BR. Human insulin resistance: the role of glucocorticoids. Diabetes Obes Metab 2003; 5: 5-12.
10. Berger J, Tanen M, Elbrecht A, et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta-hydroxysteroid dehydrogenase type 1 expression and activity. J Biol Chem 2001; 276: 12629-35.
11. Morton NM, Paterson JM, Masuzaki H, et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004; 53: 931-8.
12. Kemp BE, Mitchehill KI, Stapleton D, Michell BJ, Chen ZP, Witters LA. Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem Sci 1999; 24: 22-5.
13. Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-95.
14. Maeda N, Takahashi M, Funahashi T, et al. PPAR-gamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-9.
15. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetics. Diabetes 2002; 51: 2968-74
16. Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 2002; 143: 998-1007.
17. Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferator- activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25: 376-80.
18. Phillips SA, Ciaraldi TP, Kong APS, et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 2003; 52: 667-74.
19. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003; 14: 561-6.
20. Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004; 89: 2563-8.
21. Russell III RR, Coven DL, Pypaert M, et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004; 114: 495-503.
22. Spiegelman BM. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-14.
23. Host D, Grimaldi PA. New factors in the regulation of adipose differentiation and metabolism. Curr Opinion Lipid 2002; 13: 241-5.
24. Larsen TM, Toubro S, Astrup A. PPARγ agonists: adipogenic treatment of type II diabetes. Int J Obes 2003; 27: 147-61.
25. Carey DG, Cowin GJ, Galloway GJ, et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes Res 2002; 10: 1008-15.
26. Adams M, Montague CT, Prins JB, et al. Activators of peroxisome proliferator-activated receptor-γ have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100: 3149-53.
27. Bajaj M, Suraamornkul S, Pratipanawatr T, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003; 52: 1364-70.
28. Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89: 200-6.
29. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients in patients with type 2 diabetes mellitus. A randomized controlled trial. JAMA 2000; 283: 1695-702.
30. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI, for the Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-8.
31. Cobitz A, Ryan C, Rood J, Waterhouse B, Strachan M. Benefits beyond glycaemia of adding rosiglitazone rather than glibenclamide to metformin monotherapy in type 2 diabetes mellitus. Diabetologia 2003; 46 (Suppl. 2): A289 [Abstract 835].
32. Rosenstock J, for the Pioglitazone HCL Study Group. Improved insulin sensitivity and beta-cell responsitivity suggested by HOMA analysis of pioglitazone therapy. Diabetologia 2000; 43 (Suppl. 1): A192 [Abstract 738].
33. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE and the Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001; 12: 413-23.
34. Pavo I, Herz M, Tan M, et al., for the Pioglitazone GLAE Study Group. Pioglitazone enhances insulin sensitivity in patients with type 2 diabetes mellitus. Diabetologia 2002; 45 (Suppl.2): A250 [Abstract 779].
35. Johns D, Strand J, Halse J, et al., and the GLAC Study Group. The long-term effects of pioglitazone and glibenclamide on glycemic control and insulin sensitivity in patients with type 2 diabetes. Diabetologia 2003; 46 (Suppl.2): A287 [Abstract PS829].
36. Tan M, Herz M, Johns D, et al., and the GLAD Study Group. Long-term effects of pioglitazone and glimepiride on insulin sensitivity and glycemic control in patients with type 2 diabetes. Diabetes Metab 2003; 29 (Hors série 2): 4S252 [Abstract 2297].
37. Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin resistant patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 163-70.
38. Werner AL, Travaglini MT. A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 2001; 21: 1082-99.
39. Wagstaff AJ, Goa KL. Rosiglitazone. A review of its use in the management of type 2 diabetes mellitus. Drugs 2002; 62: 1805-37.
40. Chilcott J, Tappenden P, Jones ML, Wight JP. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther 2001; 23: 1792-823.
41. Brunetti P. Pioglitazone - current profile. Br J Diabetes Vasc Dis 2002; 2 (Suppl. 1): S18-S23.
42. Goldstein BJ. Differentiating members of the thiazolidinedione class: a focus on efficacy. Diabetes Metab Res Rev 2002; 18 (Suppl. 2): S16-S22.
43. Monnier L, Sauvanet JP. Pioglitazone, insulinosensibilité et diabète de type 2: données récentes. Ann Endocrinol 2004; 65: 136-48.
44. Blicklé JF. Place des thiazolidinediones dans le traitement du diabète de type 2. Presse Med 2004; 33: 1034-40.
45. Aronoff S, Rosenblatt S, Braithwaite S, et al., for the Pioglitazone 001 Study Group. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. A 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000; 23: 1605-11.
46. Scherbaum WA, Göke B, and the German Pioglitazone Study Group. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res 2002; 34: 589-95.
47. Nolan JJ, Jones WP, Patwardhan R, Deacon LF. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 2000; 17: 287-94.
48. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. Once- and twice daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24: 308-15.
49. Wyne KL, Cobitz AR, Waterhouse BR, Straw LJ. The effects of rosiglitazone in poorly-controlled, drug-naive patients with type 2 diabetes mellitus. Diabetologia 2004; 47 (Suppl. 1): A263 [abstract PS728].
50. Hanefeld M, Göke B. Combination pioglitazone with a sulfonylurea or metformin in the management of type 2 diabetes. Exp Clin Endocrinol Diabetes 2000; 108 (suppl. 2): S256-S266.
51. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001; 111: 10-7.
52. Wolffenbuttel BHR, Gomis R, Squatrito, Jones NP, Patwardhan R. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabet Med 2000; 17: 40-7.
53. Raskin P, McGill J, Saad MF, et al., for the Repaglinide/ Rosiglitazone Study Group. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone. Diabet Med 2004; 21: 329-35.
54. Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE. Addition of nateglinide to rosiglitazone monotherapy suppresses meal-time hyperglycemia and improves overall glycemic control. Diabetes Care 2003; 26: 1685-90.
55. Gomez-Perez FJ, Fanghänel-Salmon G, Barbosa JA, et al. Efficacy and safety of rosiglitazone in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002; 18: 127-34.
56. Einhorn D, Rendell MS, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 2000; 22: 1395-409.
57. Campbell JW. Long-term glycaemic control with pioglitazone in patients with type 2 diabetes. Int J Clin Pract 2004; 58: 192-200.
58. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH, on behalf of the QUARTET Study Group. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004; 27: 141-7.
59. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005; 21: (published online June 15, 2004).
60. Home P, Gubb J, for the RECORD study steering committee and investigators. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycemia in Diabetes (RECORD): a long-term cardiovascular outcome study. Diabetes 2002; 51 (Suppl. 2): A487 [abstract].
61. Home PD, Pocock S, Beck-Nielsen H, et al., for the RECORD Study Group. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes (RECORD): an interim analysis of glycaemia at 18 months. Diabetologia 2004; 47 (Suppl. 1): A262 [abstract PS725].
62. Oshinyemi K, Garcia S, Curtis P, Zambanini P, Stewart M. Evaluation of the effects of rosiglitazone combination therapy on ambulatory blood pressure after 6 months; a 12 month sub-study of the RECORD trial in people with type 2 diabetes mellitus. Diabetologia 2004; 47 (Suppl. 1): A262 [abstract PS724].
63. Freed MI, Ratner R, Marcovina SM, et al., on behalf of the Rosiglitazone Study 108 Investigators. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 947-52.
64. Vergès B. Antidiabétiques oraux et lipides. Ann Endocrinol 2002; 63: 1S45-1S50.
65. Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JPD. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 2004; 27: 41-6.
66. Brunzell JD, Marconiva S, Yu D, et al. Rosiglitazone reduces novel biomarkers of cardiovascular disease in subjects with type 2 diabetes mellitus already on statin therapy. J Am Coll Cardiol 2004; 43 (Suppl.A): 236 [abstract 1124-192].
67. Smith U. Pioglitazone: mechanism of action. Int J Clin Pract 2001; Suppl.121: 13-18.
68. Van Wilk JPH, De Koning EJP, Martens EP, Rabelink TJ. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003; 23: 1744-9.
69. Yu D, Murdoch SJ, Marcovina SM, et al. Effect of rosiglitazone on lipid metabolism in type 2 diabetes mellitus patients who were predominant type B LDL and on statins. Diabetes 2004; 53 (Suppl. 2): A233 [abstract 951-P].
70. Dailey GE III, Noor MA, Park JS, Bruce S, Fiedorek FT. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med 2004; 116: 223-9.
71. Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med 2004; 116: 230-5.
72. Rosenstock J, Sugimoto D, Strange P, Stewart J, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: benefits of insulin glargine over rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients. Diabetes 2004; 53 (Suppl. 2): A145 [abstract 609-P].
73. Poulsen MK, Henriksen JE, Hother-Nielsen O, Beck-Nielsen H. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care 2003; 26: 3273-9.
74. Belcher G, Matthews DR. Safety and tolerability of pioglitazone. Exp Clin Endocrinol Diabetes 2000; 108 (Suppl. 2): S267-S273.
75. Le Feuvre C. Effets cardio-vasculaires de la rosiglitazone. Presse Med 2004; 33: 735-45.
76. Raskin P, Rendell M, Riddle MC, et al., for The Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226-32.
77. Scheen A. Thiazolidinediones and liver toxicity. Diabetes Metab 2001; 27: 305-13.
78. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials. Evidence that rosiglitazone does not cause hepatic hepatic dysfunction. Diabetes Care 2002; 25: 815-21.
79. Cohen-Solal A. Précautions d'emploi et contre-indications des thiazolidinediones. Le point de vue du cardiologue. Ann Endocrinol 2002; 63: 1S51-1S55.
80. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108: 2941-8.
81. id. Diabetes Care 2004; 27: 256-63.
82. Girard J. Mécanisme d'action des thiazolidinediones. Diabetes Metab 2001; 27: 271-8.
83. Girard J. Cellule β-pancréatique, glitazones et diabète de type 2. Masson Thérapeutique Diabétologie 2003; AC B/018 (8 pages).
84. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic woman. Diabetes 2002; 51: 2796-803.
85. Xiang AH, Peters RK, Kjos SL et al. Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function. J Clin Endocrinol Metab 2004; 89: 2846-51.
86. Xiang AH, Peters RK, Kjos SL, et al. Continued protection from diabetes during treatment of the TRIPOD cohort with pioglitazone. Diabetes 2003; 52 (Suppl. 1): A75 [Abstract 322-OR].
87. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
88. The DPP Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2003; 52 (Suppl.1): A58-A59 [Abstract 251-OR].
89. Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 2004; 6: 280-5.
90. Diabetes Prevention Program Research Group. Delay and prevention of type 2 diabetes: computer modeling of the DPP. Diabetes 2004; 53 (Suppl.2): A240 [Abstract 980-P].
91. Suivi du patient diabétique de type 2 à l'exclusion du suivi des complications. Recommandations de l'ANAES. Diabetes Metab 1999; 25 (Suppl. 2): 1-64.